Business
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s
About this update from Tandem Diabetes Care, Inc.
[{"type":"text","content":"\n\nAbbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S.\n\n\n\nTandem’s Control-IQ™ hybrid closed-loop technology now integrates with the first and only 15-day continuous glucose monitoring (CGM) sensor in the U.S.1\n\n\n\n ABBOTT PARK, Ill. & SAN DIEGO--(BUSINESS WIRE)--\nAbbott (NYSE: ABT), the global health care company, and Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology. For the first time, FreeStyle Libre technology users in the United States are now able to experience the therapeutic benefits of a hybrid closed-loop system that helps predict and prevent high and low blood sugar.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108667517/en/t:slim X2 Insulin Pump from Tandem Diabetes Care with Abbott’s Freestyle Libre 2 Plus sensor integration now available in the United States. (Photo: Business Wire)\nTandem’s t:slim X2 insulin pump connects wirelessly to the FreeStyle Libre 2 Plus sensor, which sends automatic glucose readings every minute2,3 to the pump. Users can conveniently see their minute-to-minute glucose data on the pump and accompanying t:connect mobile app.4 The pump’s Control-IQ technology predicts glucose levels 30 minutes into the future, automatically adjusting insulin delivery every five minutes based on CGM readings and can deliver automatic correction boluses (up to one per hour) to help prevent hyperglycemia.5 When left untreated, hyperglycemia can lead to long-term diabetes complications, such as nerve and kidney damage or disease of the eyes.\n\n\n“Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the U.S.,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “This represents another step forward in our commitment to provide customizable solutions to help reduce burden and create new possibilities for p...